Acumen Pharmaceuticals' ACU193 shows promise as a potential treatment for early-stage Alzheimer's Disease, targeting amyloid beta oligomers with a more favorable safety profile. Q2 earnings show ...
CEO Daniel O'Connell stated that "in the third quarter, we continued our track record of operational execution on 2 fronts: the steady progression of our Phase II ALTITUDE-AD trial and the generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results